Roivant Sciences Ltd. (ROIV)
ROIV Stock Price Chart
Explore Roivant Sciences Ltd. interactive price chart. Choose custom timeframes to analyze ROIV price movements and trends.
ROIV Company Profile
Discover essential business fundamentals and corporate details for Roivant Sciences Ltd. (ROIV) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Dec 2020
Employees
908.00
Website
https://roivant.comCEO
Matthew Gline
Description
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
ROIV Financial Timeline
Browse a chronological timeline of Roivant Sciences Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 10 Aug 2026
EPS estimate is -$0.33, while revenue estimate is $2.07m.
Earnings released on 20 May 2026
EPS came in at -$0.28 surpassing the estimated -$0.29 by +3.49%, while revenue for the quarter reached $2.52m , missing expectations by -26.20%.
Earnings released on 6 Feb 2026
EPS came in at -$0.24 surpassing the estimated -$0.30 by +19.88%, while revenue for the quarter reached $2.00m , missing expectations by -60.65%.
Earnings released on 10 Nov 2025
EPS came in at -$0.20 surpassing the estimated -$0.32 by +36.86%, while revenue for the quarter reached $1.57m , missing expectations by -72.04%.
Earnings released on 11 Aug 2025
EPS came in at -$0.25 falling short of the estimated -$0.25 by -0.82%, while revenue for the quarter reached $2.17m , missing expectations by -70.28%.
Earnings released on 29 May 2025
EPS came in at -$0.29 falling short of the estimated -$0.26 by -10.05%, while revenue for the quarter reached $7.57m , missing expectations by -86.00%.
Earnings released on 10 Feb 2025
EPS came in at -$0.13 surpassing the estimated -$0.25 by +48.59%, while revenue for the quarter reached $9.02m , beating expectations by +80.36%.
Earnings released on 12 Nov 2024
EPS came in at -$0.29 falling short of the estimated -$0.25 by -17.41%, while revenue for the quarter reached $4.48m , missing expectations by -90.26%.
Earnings released on 8 Aug 2024
EPS came in at $0.12 surpassing the estimated -$0.24 by +149.32%, while revenue for the quarter reached $55.13m , beating expectations by +79.47%.
Earnings released on 30 May 2024
EPS came in at -$0.23 surpassing the estimated -$0.26 by +12.99%, while revenue for the quarter reached $28.93m , missing expectations by -6.70%.
Earnings released on 13 Feb 2024
EPS came in at -$0.21 surpassing the estimated -$0.31 by +32.04%, while revenue for the quarter reached $37.14m , beating expectations by +16.89%.
Earnings released on 13 Nov 2023
EPS came in at -$0.26 surpassing the estimated -$0.28 by +7.14%, while revenue for the quarter reached $37.10m , beating expectations by +36.88%.
Earnings released on 14 Aug 2023
EPS came in at -$0.38 falling short of the estimated -$0.26 by -46.15%, while revenue for the quarter reached $21.62m , missing expectations by -11.69%.
Earnings released on 28 Jun 2023
EPS came in at -$0.20 surpassing the estimated -$0.41 by +51.22%, while revenue for the quarter reached $27.38m , beating expectations by +50.69%.
Earnings released on 13 Feb 2023
EPS came in at -$0.49 falling short of the estimated -$0.36 by -36.11%, while revenue for the quarter reached $17.05m , beating expectations by +15.40%.
Earnings released on 14 Nov 2022
EPS came in at -$0.42 falling short of the estimated -$0.41 by -2.44%, while revenue for the quarter reached $12.53m , beating expectations by +119.85%.
Earnings released on 15 Aug 2022
EPS came in at -$0.48 falling short of the estimated -$0.30 by -60.00%, while revenue for the quarter reached $4.32m , missing expectations by -39.83%.
Earnings released on 28 Jun 2022
EPS came in at -$0.39 falling short of the estimated -$0.25 by -56.00%, while revenue for the quarter reached $9.22m , missing expectations by -30.90%.
Earnings released on 14 Feb 2022
EPS came in at -$0.41 falling short of the estimated -$0.23 by -78.26%, while revenue for the quarter reached $24.34m , beating expectations by +146.72%.
Earnings released on 15 Nov 2021
EPS came in at -$0.26 surpassing the estimated -$0.45 by +42.22%, while revenue for the quarter reached $13.99m , beating expectations by +93.66%.
Earnings released on 21 Sept 2021
Earnings released on 10 Aug 2021
ROIV Stock Performance
Access detailed ROIV performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
